Gedeon Richter buys Consilient Health’s contraceptive range for £32.5M
Gedeon Richter buys Consilient health’s contraceptive range for £32.5M
Multinational pharmaceutical company, Gedeon Richter UK Ltd, announced this week that it has acquired full marketing and distribution rights to a contraceptive range of branded generics.
The branded generic pills including seven combined oral contraceptives and one progestogen-only pill were acquired from Consilient Health for the sum of £32.5million.
Under the terms of the transfer, Gedeon Richter has become the Marketing Authorisation holder in the UK for all products within the range.
“Our mission is to provide high-quality products at affordable prices,” said Tamas Neubauer, managing director UK and Ireland, Gedeon Richter.
“The UK is experiencing a period of austerity post-pandemic, with the government looking to rein in spending across the health care system. The addition of eight branded generics to our oral contraception offering reinforces our position as a leader in family planning solutions, and partner to the NHS in helping achieve cost-savings – without compromising the ability of women to plan pregnancy around their lives.”
The company said the deal is a ‘good strategic fit for Gedeon Richter, bringing meaningful expansion to the company’s oral contraception franchise’.
The newly transferred products are the first and only branded generics in the company’s oral contraceptive range.
The transfer follows a trend the company says it has adopted across its family planning solutions more broadly, whereby the company is providing branded or hybrid generics of other methods such as the intrauterine system (IUS), alongside branded originators.
As part of the transfer, Gedeon Richter said it has committed to continuing support healthcare professionals with educational content about the products, as well as to providing information to UK women who have been prescribed one of the branded oral contraceptives in the range.
“We have years of experience supporting women’s reproductive health and we are pleased to have branded generics as part of our oral contraceptive range for the first time,” said David Jordan, Medical Director UK and Ireland, Gedeon Richter.
“Choice plays an important role when selecting a suitable contraceptive. We’re proud to provide multiple options at different price points to the NHS, with a view to ensuring women can choose a contraceptive method that’s right for them, and have the confidence it will be available in the UK long-term.”
In its research the company found that in England, between 2017-2018, more than 3.1 million women who received contraception from the GP or pharmacies took either the combined pill or progestogen-only pill.
